ClinicalTrials.gg
CompletedNCT06323421MindCRCUpdated Oct 27, 2026Results posted

Targeting Chronic Stress for Reducing Risk Factors for Colorectal Cancer

An interventional study of Mindfulness in Mindfulness, Colon Cancer and Females, sponsored by University of Illinois Chicago. Completed at 1 site in United States. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Illinois Chicago · Not applicable, Interventional, and Prevention

How we know

Updated Oct 27, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Enrollment
601st of 865
24 · median 50
Started
2024
with 25 others
No phase
264 of 1,123
29 open now
Registered
1,041st of 1,123
by date

Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 601st largest by enrollment of the 865 interventional ones that give a count, is one of 26 that started in 2024, is one of 264 with no phase, and was the 1,041st registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 45 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,123 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Many neighborhoods in Chicago experience daily exposure to stressors including economic inopportunity and violent crime in public spaces. There is mounting evidence that chronic psychosocial stress can facilitate carcinogenesis by modulating the gut microbiome and immune system. The proposed research aims to study the practice of mindfulness to mitigate CPS and reduce colorectal cancer risk factors among Black American women at elevated risk.

Read the detailed description

Chronic stress can directly and indirectly promote carcinogenesis through immune, metabolic, and microbial pathways. Our overarching hypothesis is that reducing chronic stress will have important implications for colon cancer risk reduction among vulnerable and high-risk populations. A promising approach for reducing chronic stress is mindfulness practices. Mindfulness is a meditation-based technique to achieve a state of mind used to experience higher awareness or consciousness. We propose to pilot test an 8-week Mindfulness intervention delivered in a hybrid format (synchronous and asynchronous sessions) among 40 Black females at elevated risk of colon cancer, who reside in vulnerable communities and who report moderate to high perceived stress. At baseline and post-intervention, participants will provide blood and stool undergo body composition analysis, and complete mood and lifestyle-related surveys. The specific aims are to: test the feasibility and acceptability of the intervention and evaluate the preliminary effect on stress and weight, fasting glucose, inflammation markers, and the gut microbiome - risk markers and risk pathways associated with colon tumorigenesis. While relieving social stressors is the paramount goal, addressing chronic stress at the individual level is achievable now, with implications for CRC risk reduction. If successful, data generated here will serve in developing a fully powered trial to test if MBSR is efficacious for CRC risk reduction among high-risk vulnerable populations in Chicago.

03

Conditions studied

  • Mindfulness
  • Colon Cancer
  • Females

Browse trials for

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female based on sex assigned at birth
  • Self-identify as Black
  • Age 45-65 years old
  • Completed a colonoscopy in the past 24 months,
  • Classify as elevated risk of CRC defined as: any colorectal adenoma detected in past 24 months
  • Own and use a smartphone, computer, or tablet with access to the Internet
  • Score ≥ 14 on the PSS at screening
  • Reside in a Chicago community with high violent crime

Exclusion criteria

Exclusion Criteria:

  • History of CRC
  • Antibiotics (oral/IV) in the past 2 months
  • Inflammatory bowel disease or genetic predisposition to CRC
  • Cancer diagnosis or cancer treatment in the past 12 months
  • Consume > 50 grams of ethanol daily
  • Use combustible tobacco
  • Bariatric surgery or bowel resection
  • Immunodeficiency/ disease
  • Uncontrolled diabetes ( > 9% based on EHR)
  • Fiber or pre-/probiotic supplements > 3 days per week
  • Serrated adenoma at the recent colonoscopy given the molecular features are distinct
  • Significant health conditions or take medications that impact participation or expected outcomes (e.g., β-blocker, Cushing's syndrome, and - inhaled, topical, oral in the past month given effects on hair cortisol measurement)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Mindfulness

    8-week group and individual mindfulness training and practice

    Behavioral: Mindfulness

Interventions

  • BehavioralMindfulness

    Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.

06

What researchers measure

Primary outcomes

  1. Recruitment Feasibility

    Feasible if ≥ 30% of those approached enroll at a

    Time frame: Monitored across the duration of trial (~12 months)

  2. Percent of Participant Retained at Post-intervention Data Collection

    % retained at post-intervention data collection

    Time frame: Retention to post-intervention data collection, 8-9 weeks

Secondary outcomes

  1. % of Sessions Attended

    % of sessions attended including the retreat

    Time frame: week 1 through 8 including the retreat

  2. Engagement With Mindfulness Website, Mean Weekly Minutes and Standard Deviation

    Engagement with mindfulness website assessed as mean weekly minutes and standard deviation across the 8 week intervention

    Time frame: Assessed weeks 1 - 8 of the mindfulness intervention.

Other outcomes

  1. Change in Body Mass Index

    weight in kg divided by height in meters squared, pre - post intervention

    Time frame: Baseline and post-intervention at week 9

  2. Perceived Stress Scale Score

    Change in perceived stress scale score between baseline and post-intervention, pre-post Scale is 0-40 with higher scores reflecting higher perceived stress.

    Time frame: Baseline and post-intervention at week 9

  3. Fasting Glucose

    Change in serum fasting glucose between baseline and follow-up, pre - post

    Time frame: Baseline and post-intervention at week 9

  4. Hemoglobin A1c

    Change from baseline to post-intervention in % glycated hemoglobin

    Time frame: Baseline to post-intervention at week 9

  5. Systolic Blood Pressure mmHg

    Change in systolic blood pressure between baseline and post-intervention, pre - post

    Time frame: from baseline to week 9

  6. Diastolic Blood Pressure, mmHg

    Change in diastolic blood pressure between baseline and post-intervention, pre - post

    Time frame: baseline to week 9

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneMindfulness
Started24
Completed20
Not completed4

Outcome measures

PrimaryRecruitment Feasibility

Feasible if ≥ 30% of those approached enroll at a

Time frame:
Monitored across the duration of trial (~12 months)
Reported as:
Count of participants · Participants
Recruitment Feasibility
ParticipantsMindfulness
Recruitment Feasibility24
PrimaryPercent of Participant Retained at Post-intervention Data Collection

% retained at post-intervention data collection

Time frame:
Retention to post-intervention data collection, 8-9 weeks
Reported as:
Count of participants · Participants
Percent of Participant Retained at Post-intervention Data Collection
ParticipantsMindfulness
Percent of Participant Retained at Post-intervention Data Collection20
Secondary% of Sessions Attended

% of sessions attended including the retreat

Time frame:
week 1 through 8 including the retreat
Reported as:
Mean · percentage
% of Sessions Attended
percentageMindfulness
% of Sessions Attended69.7 ± 19.7
SecondaryEngagement With Mindfulness Website, Mean Weekly Minutes and Standard Deviation

Engagement with mindfulness website assessed as mean weekly minutes and standard deviation across the 8 week intervention

Time frame:
Assessed weeks 1 - 8 of the mindfulness intervention.
Reported as:
Mean · minutes
Engagement With Mindfulness Website, Mean Weekly Minutes and Standard Deviation
minutesMindfulness
Engagement With Mindfulness Website, Mean Weekly Minutes and Standard Deviation30.33 ± 38.12
Other pre-specifiedChange in Body Mass Index

weight in kg divided by height in meters squared, pre - post intervention

Time frame:
Baseline and post-intervention at week 9
Reported as:
Mean · kg/m^2
Change in Body Mass Index
kg/m^2Mindfulness
Change in Body Mass Index-0.12 ± 1.66
Other pre-specifiedPerceived Stress Scale Score

Change in perceived stress scale score between baseline and post-intervention, pre-post Scale is 0-40 with higher scores reflecting higher perceived stress.

Time frame:
Baseline and post-intervention at week 9
Reported as:
Mean · score on a scale
Perceived Stress Scale Score
score on a scaleMindfulness
Perceived Stress Scale Score-8.45 ± 5.50
Other pre-specifiedFasting Glucose

Change in serum fasting glucose between baseline and follow-up, pre - post

Time frame:
Baseline and post-intervention at week 9
Reported as:
Mean · mg/dl
Fasting Glucose
mg/dlMindfulness
Fasting Glucose3.53 ± 9.57
Other pre-specifiedHemoglobin A1c

Change from baseline to post-intervention in % glycated hemoglobin

Time frame:
Baseline to post-intervention at week 9
Reported as:
Mean · percentage of glycated hemoglobin
Hemoglobin A1c
percentage of glycated hemoglobinMindfulness
Hemoglobin A1c-0.03 ± 0.22
Other pre-specifiedSystolic Blood Pressure mmHg

Change in systolic blood pressure between baseline and post-intervention, pre - post

Time frame:
from baseline to week 9
Reported as:
Mean · mmHg
Systolic Blood Pressure mmHg
mmHgMindfulness
Systolic Blood Pressure mmHg-9.22 ± 12.62
Other pre-specifiedDiastolic Blood Pressure, mmHg

Change in diastolic blood pressure between baseline and post-intervention, pre - post

Time frame:
baseline to week 9
Reported as:
Mean · mmHg
Diastolic Blood Pressure, mmHg
mmHgMindfulness
Diastolic Blood Pressure, mmHg-1.32 ± 8.45

Adverse events

Collected over From baseline to post-intervention data collection, up to 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mindfulness0/24 (0%)0/24 (0%)0/24 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mindfulness
Mean55.62 ± 5.83
Sex: Female, Male
Sex: Female, Male(Participants)Mindfulness
Female24
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mindfulness
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American24
White0
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • University of Illinois Chicago
    Chicago, Illinois 60612, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jul 2025, 11 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's 11 months is below that.

Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 21, 2024
StartActual
Jul 15, 2024
Primary completionActual
Jul 10, 2025
CompletionActual
Jul 10, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedRecruitment Feasibility measuresTime frame: Monitored across the duration of study and 8-week intervention → Monitored across the duration of trial (~12 months)
  • ChangedBefore AcceptabilityNow Percent of Participant Retained at Post-intervention Data CollectionTime frame: Week 4 and post-intervention at week 9 → Retention to post-intervention data collection, 8-9 weeks
Oct 27, 2026
Documents
Secondary outcomes
2 edited, 1 time frame changed, 5 added, 11 removed, 1 description edited
What changed in the outcomes
  • Added% of Sessions AttendedTime frame: week 1 through 8 including the retreat
  • AddedEngagement With Mindfulness Website, Mean Weekly Minutes and Standard DeviationTime frame: Assessed weeks 1 - 8 of the mindfulness intervention.
  • Editedother outcomeChange in Body mass indexMass IndexTime frame: Baseline and post-intervention at week 9
  • Editedother outcomeFasting glucoseGlucoseTime frame: Baseline and post-intervention at week 9
  • Addedother outcomePerceived Stress Scale ScoreTime frame: Baseline and post-intervention at week 9
  • Addedother outcomeSystolic Blood Pressure mmHgTime frame: from baseline to week 9
  • Addedother outcomeDiastolic Blood Pressure, mmHgTime frame: baseline to week 9
  • Removedother outcomeStress measureTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeGut microbiota compositionTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeGut inflammationTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeAdiposityTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeEpinephrineTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeNorepinephrineTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeCortisolTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeResting heart rateTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeBlood lipidsTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeFasting insulinTime frame: Baseline and post-intervention at week 9
  • Removedother outcomeSystemic inflammationTime frame: Baseline and post-intervention at week 9
  • Time frameother outcomeHemoglobin A1cBaseline and post-intervention at week 9 → Baseline to post-intervention at week 9
  • Descriptionother outcomeHemoglobin A1c: how it is measured was reworded
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedRecruitment Feasibility measuresTime frame: Monitored across the duration of study and 8-week intervention → Monitored across the duration of trial (~12 months)
    • ChangedBefore AcceptabilityNow Percent of Participant Retained at Post-intervention Data CollectionTime frame: Week 4 and post-intervention at week 9 → Retention to post-intervention data collection, 8-9 weeks
    Secondary outcomes 2 edited, 1 time frame changed, 5 added, 11 removed, 1 description edited
    What changed in the outcomes
    • Added% of Sessions AttendedTime frame: week 1 through 8 including the retreat
    • AddedEngagement With Mindfulness Website, Mean Weekly Minutes and Standard DeviationTime frame: Assessed weeks 1 - 8 of the mindfulness intervention.
    • Editedother outcomeChange in Body mass indexMass IndexTime frame: Baseline and post-intervention at week 9
    • Editedother outcomeFasting glucoseGlucoseTime frame: Baseline and post-intervention at week 9
    • Addedother outcomePerceived Stress Scale ScoreTime frame: Baseline and post-intervention at week 9
    • Addedother outcomeSystolic Blood Pressure mmHgTime frame: from baseline to week 9
    • Addedother outcomeDiastolic Blood Pressure, mmHgTime frame: baseline to week 9
    • Removedother outcomeStress measureTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeGut microbiota compositionTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeGut inflammationTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeAdiposityTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeEpinephrineTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeNorepinephrineTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeCortisolTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeResting heart rateTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeBlood lipidsTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeFasting insulinTime frame: Baseline and post-intervention at week 9
    • Removedother outcomeSystemic inflammationTime frame: Baseline and post-intervention at week 9
    • Time frameother outcomeHemoglobin A1cBaseline and post-intervention at week 9 → Baseline to post-intervention at week 9
    • Descriptionother outcomeHemoglobin A1c: how it is measured was reworded
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06323421
Lead sponsor
University of Illinois Chicago
Responsible party
Lisa Tussing-Humphreys (Professor, University of Illinois Chicago) — Principal investigator
First posted
Mar 21, 2024
Start date
Jul 15, 2024
Primary completion
Jul 10, 2025
Completion
Jul 10, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Lisa Tussing-Humphreys
principal investigator · University of Illinois Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion